The antibiotics were subsequently given by the oral route (co-trimoxazole at the same dosage and ciprofloxacin at 250 mg tds) and, after 2 weeks, the dosages were reduced (co-trimoxazole 480 mg bd and ciprofloxacin 250 mg bd). The patient completed a 4 week course of this regimen, during which time she remained afebrile. She was discharged and, at a 6 month follow-up assessment, was well and exhibited no signs of relapse.
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Sir, Coagulase-negative staphylococci have been increasingly recognized as important causes of nosocomial bacteraemia, especially in immunocompromised patients.
1,2 Various factors have contributed to this increase, including the use of central venous catheters, the administration of more aggressive anti-neoplastic chemotherapy, greater awareness of the clinical significance of coagulase-negative staphylococci and improvements in microbiological techniques that have facilitated the identification of these pathogens. In recent years, there have been reports of higher incidences of resistance amongst coagulasenegative staphylococci strains, 50% of isolates having been shown to be resistant to methicillin.
3 A consequence of the rising incidence of methicillin resistance has been the more widespread use of glycopeptides (vancomycin and teicoplanin) as empirical therapy of patients with haematological malignancies who present with fevers of unknown origin. This practice has, in turn, almost certainly contributed to the increase in teicoplanin resistance that has been observed amongst coagulase-negative staphylococci 4 and, much less commonly, to the isolation of vancomycinresistant strains.
5 To the best of our knowledge, there have been no previous studies that have used a statistical approach to identify the clinical parameters that influence the development of drug resistance. We have therefore investigated the impact of bacteraemias caused by glycopeptide-resistant strains of coagulase-negative staphylococci on patients with haematological malignancies admitted under our care between January 1990 and D ecember 1996 and have used univariate and multivariate statistical analyses to identify the risk factors associated with the development of resistance to teicoplanin amongst coagulase-negative staphylococci.
The diagnosis of coagulase-negative staphylococcal bacteraemia was based on the isolation of a strain of coagulase-negative staphylococci from at least two sets of blood cultures obtained from a patient with signs and symptoms consistent with septicaemia. Cases were defined as those from whom coagulase-negative staphylococci strains resistant to teicoplanin were isolated, while controls were defined as those from whom strains susceptible to teicoplanin were isolated. The following data were recorded in respect of all patients included in the study: age; sex; type and stage of haematological malignancy; whether or not the patient was experiencing relapse of the underlying disease; duration of hospital stay; hospitalization within the previous month; and the pattern of in-vitro susceptibility of the pathogen to anti-staphylococcal antibiotics. The significance of each of the following additional factors which might be associated with the development of resistance to teicoplanin amongst coagulase-negative staphylococci strains causing bacteraemias was also assessed: number of circulating polymorphonuclear leucocytes (PMNL); use of steroids; administration of antineoplastic chemotherapy; recent administration of broadspectrum antibiotics (in particular glycopeptides); prophylaxis with fluoroquinolones in the previous 30 days; presence of a central venous catheter; and presence of mucositis or decubitus ulcers. Neutropenia was defined as 0.5 10 9 PMNL/L and nosocomial bacteraemia as an episode of bacteraemia presenting at least 48 h after hospital admission.
A ntimicrobial susceptibility was determined by a microbroth dilution method, as recommended by the National Committee for Clinical Laboratory Standards, 6 and resistance to teicoplanin was confirmed by repeating the test.
The chi-squared test and Student's t-test were used for the statistical analyses of the characteristics of the two groups (cases and controls) and 95% test-based confidence intervals (CI) were used to determine the statistical significance of the odds ratio (O R ). Multivariate analysis was used to adjust for possible confounding variables. The statistical analyses were performed with the software program, E gret (Statistics and E pidemiology R esearch Corporation, Seattle, WA ).
Sixty-three bacteraemic episodes caused by coagulasenegative staphylococci, representing 37% of all episodes of bacteraemia occurring in haematological patients during the study period, were recorded. The aetiological agents were Staphylococcus epiderm idis (56 cases), Staphylococcus hom inis (two), Staphylococcus xylosus (two), Staphylococcus haem olyticus (two) and Staphylococcus cohnii (one). Seventy-one per cent of the episodes were nosocomial and 29% were community-acquired. The presumed foci of the bacteraemias included central venous catheters (61% ), skin and soft tissues (11% ), intravenous drug abuse (2% ) and unknown (26% ). E ighteen of the 56 (32% ) isolates tested were resistant to teicoplanin (MICs 32 mg/L). D uring the study period, there was an increase in the incidence of isolation of teicoplanin-resistant strains, from 3% in 1990 to 7% in 1994 and 18% in 1996 (P 0.03; 2 for trend). O f the other antibiotics to which susceptibilities were determined, 46 of 63 (73% ) strains tested were resistant to methicillin, 41 of 53 (77% ) were resistant to ciprofloxacin and 34 of 44 (77% ) were resistant to gentamicin. None of the isolates was resistant to vancomycin, but many (51% ) were resistant to multiple (i.e. three or more) agents.
U nivariate analysis revealed that previous antibiotic therapy (P 0.02; O R 3.86; 95% CI 1.07 14.35), neutropenia ( P 0.03; O R 3.5; 95% CI 1.32 3.08), central venous catheter usage (P 0.02; O R = 4; 95% CI 1.09 15.1) and prolonged duration of hospitalization (P 0.03; 2 for trend) were significantly associated with resistance to teicoplanin amongst CoNS isolates. H owever, multivariate analysis showed only previous antibiotic therapy (P 0.01; O R 6.32; 95% CI 2.31 17.51) and prolonged duration of hospitalization (P 0.03; 2 for trend) to be independent risk factors for the development of resistance to this agent. Surprisingly, the previous administration of teicoplanin was not significantly linked to teicoplanin resistance, although the P value (0.06) approached statistical significance. No statistically significant association with resistance to teicoplanin was demonstrated for the following parameters: age; sex; type and stage of underlying malignancy; use of steroids; use of chemotherapy; use of antibiotic prophylaxis; or the presence of mucositis or decubitus ulcers.
A ll patients with bacteraemias caused by coagulasenegative staphylococci were initially treated with antibiotic regimens that included an agent with reliable activity against coagulase-negative staphylococci, although the regimen was subsequently modified, if necessary, when the results of susceptibility testing became available. The response to therapy was favourable in 56 (89% ) episodes, while death was the outcome in seven (11% ); relapses were observed on six (10% ) occasions. With regard to the 18 episodes of bacteraemia caused by teicoplanin-resistant strains, four (22% ) of the patients died. H owever, in all of these cases, the bacteraemic episodes could have been the terminal events in a setting of multiple opportunistic infections occurring in patients in the advanced stages of haematological malignancy. The outcome of bacteraemia was significantly affected by the stage of haematological disease ( P 0.01; O R 3.21; 95% CI 1.21 7.51) and causation by multidrug-resistant pathogens (P 0.03; O R 2.01; 95% CI 1.11 7.65), but not by the administration of prophylactic antibiotics, the use of central venous catheters or profound neutropenia.
The results of this study confirm that the incidence of infections caused by coagulase-negative staphylococci in patients with haematological malignancies is rising, with high percentages ( 50% ) of isolates being resistant to both methicillin and ciprofloxacin, and emphasize the potential for teicoplanin resistance to develop in these pathogens. The progressive increase in the annual incidence of bacteraemic episodes caused by teicoplanin-resistant coagulase-negative staphylococci which was observed during the study period (from 3% to 18% ) is probably related to a number of factors, including characteristics of both the host and the pathogen and increasing antibiotic pressures. A s expected, multivariate analysis demonstrated that teicoplanin resistance is related to prolonged hospitalization and the previous administration of broad-spectrum antibiotics. O ur findings also confirm that the excellent invitro activity of vancomycin against coagulase-negative staphylococci isolates has been preserved and that crossresistance between glycopeptides is not inevitable. O n the other hand, we believe that the inappropriate empirical use of vancomycin, e.g. in patients with fevers of unknown origin, could lead to the development of resistance to this agent amongst coagulase-negative staphylococci, a situation that has already been observed amongst E nterococcus spp.
